Abstract P023

Real-World Effectiveness and Safety of the BrECADD Regimen in Advanced Hodgkin Lymphoma. A Multicenter Observational Study of the Polish Lymphoma Research Group.

Introduction: The BrECADD regimen has demonstrated high efficacy in patients with advanced Hodgkin lymphoma (HL).

Aim: The aim of this observational study conducted by the Polish Lymphoma Research Group (PLRG) was to assess the efficacy and safety of the BrECADD regimen in patients with advanced HL treated in real-world clinical practice.

Materials and methods: Clinical data from patients with HL treated in 12 hematology centers in Poland were retrospectively evaluated. The analysis included 61 patients: 30 women and 31 men, diagnosed with advanced-stage HL. The mean age was 33 years. According to the Ann Arbor classification, 15 patients had stage III disease and 46 had stage IV . B symptoms were present in 43 patients (70.5%), while extranodal involvement was confirmed in 45 patients (75%). Statistical analyses were performed using R software. Categorical variables were presented as n (%), while continuous variables were expressed as mean ± standard deviation due to their normal distribution. Normality of distribution was assessed using the Shapiro–Wilk test and additionally verified by skewness and kurtosis analyses.

Results: The median number of administered cycles was 4. Interim PET/CT assessment after 2 cycles was performed in 53 patients and demonstrated complete remission (CR) in 40 patients (75%) and partial remission (PR) in 12 patients (22.6%). Disease progression (PD) was observed in 1 patient.PET/CT assessment after 4 cycles was available in 39 patients and confirmed CR in 34 patients (87%), while PD was observed in 2 patients (5%). Progression-free survival (PFS) in the overall analyzed cohort was 97.1% at 6 months. Grade 3–4 neutropenia occurred in 40 patients (89%), thrombocytopenia with platelet count below 20 G/L was observed in 13 patients (21%). Febrile neutropenia developed in 13 patients (21%). Dose reduction of brentuximab vedotin was required in 12 patients (19%), whereas dose reductions of other agents (cyclophosphamide and etoposide) were necessary in 19 patients (31%).

Conclusion: Our preliminary real-world data confirm the high efficacy of the BrECADD regimen in patients with advanced HL, with high complete remission rates and excellent short-term PFS. Although hematologic toxicity was frequent, adverse events were manageable and consistent with the known safety profile of the regimen. These findings support the implementation of BrECADD as an effective first-line treatment option for advanced HL in Poland.